Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism MDM2 modulators(p53-binding protein Mdm-2 modulators), p53 inhibitors(Tumor protein p53 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Preclinical | US | 17 Apr 2023 |